Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2014

Open Access 01-12-2014 | Research

The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study

Authors: Dmitrij Achelrod, Carl Rudolf Blankart, Roland Linder, Yskert von Kodolitsch, Tom Stargardt

Published in: Orphanet Journal of Rare Diseases | Issue 1/2014

Login to get access

Abstract

Background

Marfan syndrome is a rare disease of the connective tissues, affecting multiple organ systems. Elevated morbidity and mortality in these patients raises the issue of costs for sickness funds and society. To date, there has been no study analysing the costs of Marfan syndrome from a sickness fund and societal perspective.

Objective

To estimate excess health resource utilisation, direct (non-)medical and indirect costs attributable to Marfan syndrome from a healthcare payer and a societal perspective in Germany in 2008.

Methods

A retrospective matched cohort study design is applied, using claims data. For isolating the causal effect of Marfan syndrome on excess costs, a genetic matching algorithm was used to reduce differences in observable characteristics between Marfan syndrome patients and the control group. 892 patients diagnosed with Marfan syndrome (ICD-10 Q87.4) were matched from a pool of 26,645 control individuals. After matching, we compared health resource utilisation and costs.

Results

From the sickness fund perspective, an average Marfan syndrome patient generates excess annual costs of €2496 compared with a control individual. From the societal perspective, excess annual costs amount to €15,728. For the sickness fund, the strongest cost drivers are inpatient treatment and care by non-physicians. From the sickness fund perspective, the third (25–41 years) and first (0–16 years) age quartiles reveal the greatest surplus in total costs. Marfan syndrome patients have 39% more physician contacts, a 153% longer average length of hospital stay, 119% more inpatient stays, 33% more prescriptions, 236% more medical imaging and 20% higher average prescription costs than control individuals. Depending on the prevalence, the economic impact from the sickness fund perspective ranges between €24.0 million and €61.4 million, whereas the societal economic impact extends from €151.3 million to €386.9 million.

Conclusions

Relative to its low frequency, Marfan syndrome requires high healthcare expenditure. Not only the high costs of Marfan syndrome but also its burden on patients’ lives call for more awareness from policy-makers, physicians and clinical researchers. Consequently, the diagnosis and treatment of Marfan syndrome should begin as soon as possible in order to prevent disease complications, early mortality and substantial healthcare expenditure.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Yetman AT, Bornemeier RA, McCrindle BW: Long-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death?. J Am Coll Cardiol. 2003, 41: 329-332.CrossRefPubMed
4.
5.
6.
Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC: Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003, 33: 407-411.CrossRefPubMed
7.
Bolar N, Van Laer L, Loeys BL: Marfan syndrome: from gene to therapy. Curr Opin Pediatr. 2012, 24: 498-504.CrossRefPubMed
8.
Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM: The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010, 47: 476-485.CrossRefPubMed
9.
Brown OR, DeMots H, Kloster FE, Roberts A, Menashe VD, Beals RK: Aortic root dilatation and mitral valve prolapse in Marfan’s syndrome: an ECHOCARDIOgraphic study. Circulation. 1975, 52: 651-657.CrossRefPubMed
10.
Kiotsekoglou A, Sutherland GR, Moggridge JC, Nassiri DK, Camm AJ, Child AH: The unravelling of primary myocardial impairment in Marfan syndrome by modern echocardiography. Heart. 2009, 95: 1561-1566.CrossRefPubMed
11.
Rybczynski M, Bernhardt AMJ, Rehder U, Fuisting B, Meiss L, Voss U, Habermann C, Detter C, Robinson PN, Arslan-Kirchner M, Schmidtke J, Mir TS, Berger J, Meinertz T, von Kodolitsch Y: The spectrum of syndromes and manifestations in individuals screened for suspected Marfan syndrome. Am J Med Genet A. 2008, 146A: 3157-3166.CrossRefPubMed
12.
Faivre L, Collod-Beroud G, Loeys BL, Child A, Binquet C, Gautier E, Callewaert B, Arbustini E, Mayer K, Arslan-Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N, Dietz HC, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Muti C, Plauchu H, Robinson PN, Adès LC, Biggin A, Benetts B, Brett M, Holman KJ, De Backer J, Coucke P, Francke U, De Paepe A, et al, et al: Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet. 2007, 81: 454-466.CrossRefPubMedPubMedCentral
13.
Marsalese DL, Moodie DS, Vacante M, Lytle BW, Gill CC, Sterba R, Cosgrove DM, Passalacqua M, Goormastic M, Kovacs A: Marfan’s syndrome: natural history and long-term follow-up of cardiovascular involvement. J Am Coll Cardiol. 1989, 14: 422-428. discussion 429–431CrossRefPubMed
14.
Benedetto U, Melina G, Takkenberg JJM, Roscitano A, Angeloni E, Sinatra R: Surgical management of aortic root disease in Marfan syndrome: a systematic review and meta-analysis. Heart. 2011, 97: 955-958.CrossRefPubMed
15.
Chow K, Pyeritz RE, Litt HI: Abdominal visceral findings in patients with Marfan syndrome. Genet Med. 2007, 9: 208-212.CrossRefPubMed
16.
Détaint D, Faivre L, Collod-Beroud G, Child AH, Loeys BL, Binquet C, Gautier E, Arbustini E, Mayer K, Arslan-Kirchner M, Stheneur C, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Plauchu H, Robinson PN, Kiotsekoglou A, De Backer J, Adès L, Francke U, De Paepe A, Boileau C, Jondeau G: Cardiovascular manifestations in men and women carrying a FBN1 mutation. Eur Heart J. 2010, 31: 2223-2229.CrossRefPubMed
17.
Jondeau G, Michel JB, Boileau C: The translational science of Marfan syndrome. Heart. 2011, 97: 1206-1214.CrossRefPubMed
18.
De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE: Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet. 1996, 62: 417-426.CrossRefPubMed
19.
Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, Boxer M, Devereux RB, Tsipouras P: Life expectancy in the Marfan syndrome. Am J Cardiol. 1995, 75: 157-160.CrossRefPubMed
20.
Gott VL, Greene PS, Alejo DE, Cameron DE, Naftel DC, Miller DC, Gillinov AM, Laschinger JC, Borst HG, Cabrol CEA, Cooley DA, Coselli JS, David TE, Griepp RB, Kouchoukos NT, Turina MI, Pyeritz RE: Replacement of the aortic root in patients with Marfan’s syndrome. N Engl J Med. 1999, 340: 1307-1313.CrossRefPubMed
21.
Kallenbach K, Karck M, Leyh RG, Hagl C, Walles T, Harringer W, Haverich A: Valve-sparing aortic root reconstruction in patients with significant aortic insufficiency. Ann Thorac Surg. 2002, 74: S1765-S1768. discussion S1792–1799CrossRefPubMed
22.
Bernhardt AMJ, Treede H, Rybczynski M, Sheikzadeh S, Kersten JF, Meinertz T, von Kodolitsch Y, Reichenspurner H: Comparison of aortic root replacement in patients with Marfan syndrome. Eur J Cardiothorac Surg. 2011, 40: 1052-1057.PubMed
23.
Murdoch JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA: Life expectancy and causes of death in the Marfan syndrome. N Engl J Med. 1972, 286: 804-808.CrossRefPubMed
24.
Pyeritz RE: Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart. 2009, 95: 173-175.CrossRefPubMed
25.
Silverman DI, Gray J, Roman MJ, Bridges A, Burton K, Boxer M, Devereux RB, Tsipouras P: Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. J Am Coll Cardiol. 1995, 26: 1062-1067.CrossRefPubMed
26.
Ladouceur M, Fermanian C, Lupoglazoff J-M, Edouard T, Dulac Y, Acar P, Magnier S, Jondeau G: Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol. 2007, 99: 406-409.CrossRefPubMed
27.
Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB, Klein GL, Li JS, Minich LL, Paridon SM, Pearson GD, Printz BF, Pyeritz RE, Radojewski E, Roman MJ, Saul JP, Stylianou MP, Mahony L, Pediatric Heart Network Investigators: Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J. 2007, 154: 624-631.CrossRefPubMedPubMedCentral
28.
Aldrich HR, Labarre RL, Roman MJ, Rosen SE, Spitzer MC, Devereux RB: Color flow and conventional echocardiography of the Marfan syndrome. Echocardiography. 1992, 9: 627-636.CrossRefPubMed
29.
Settepani F, Szeto WY, Pacini D, De Paulis R, Chiariello L, Di Bartolomeo R, Gallotti R, Bavaria JE: Reimplantation valve-sparing aortic root replacement in Marfan syndrome using the Valsalva conduit: an intercontinental multicenter study. Ann Thorac Surg. 2007, 83: S769-S773. discussion S785–790CrossRefPubMed
30.
Bernhardt AM, Treede H, Detter C, Rybczynski M, Sheikhzadeh S, Wagner FM, Von Kodolitsch Y, Reichenspurner H: Results of modern mitral valve repair in patients with Marfan syndrome. Thorac Cardiovasc Surg. 2014, 62: 35-41.PubMed
31.
LeMaire SA, Carter SA, Volguina IV, Laux AT, Milewicz DM, Borsato GW, Cheung CK, Bozinovski J, Markesino JM, Vaughn WK, Coselli JS: Spectrum of aortic operations in 300 patients with confirmed or suspected Marfan syndrome. Ann Thorac Surg. 2006, 81: 2063-2078. discussion 2078CrossRefPubMed
32.
Peters KF, Horne R, Kong F, Francomano CA, Biesecker BB: Living with Marfan syndrome II. Medication adherence and physical activity modification. Clin Genet. 2001, 60: 283-292.CrossRefPubMed
33.
34.
Manow M-L, Paulsen N, Rybczynski M, Mir T, Bernhardt AMJ, Treede H, Ohm G, Fuisting B, Rehder U, Meier F, Vogler M, Meinertz T, Overlack K, von Kodolitsch Y: [Analysis of costs and profits of ambulatory care of Marfan patients after initiation of a novel German legal directive (116 b SGB V)]. Med Klin (Munich). 2010, 105: 529-537.CrossRef
35.
36.
Roll K: The influence of regional health care structures on delay in diagnosis of rare diseases: the case of Marfan syndrome. Health Policy. 2012, 105: 119-127.CrossRefPubMed
37.
Sekhon JS: Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Software. 2011, 42: 1-52.CrossRef
38.
Mebane WR, Sekhon JS: Genetic optimization using derivatives: the rgenoud package for R. J Stat Software. 2011, 42: 1-26.CrossRef
39.
40.
Statistisches Bundesamt: Entwicklung der Bruttoverdienste. 2008, Bonn: Statistisches Bundesamt
41.
42.
Statistisches Bundesamt: Gesundheitsausgabenrechnung. 2008, Bonn: Statistisches Bundesamt
43.
Peters KF, Kong F, Horne R, Francomano CA, Biesecker BB: Living with Marfan syndrome I. Perceptions of the condition. Clin Genet. 2001, 60: 273-282.CrossRefPubMed
44.
De Bie S, De Paepe A, Delvaux I, Davies S, Hennekam RCM: Marfan syndrome in Europe. Community Genet. 2004, 7: 216-225.CrossRefPubMed
45.
Magliano L, Fiorillo A, De Rosa C, Malangone C, Maj M, National Mental Health Project Working Group: Family burden in long-term diseases: a comparative study in schizophrenia vs. physical disorders. Soc Sci Med. 2005, 61: 313-322.CrossRefPubMed
46.
Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures for use with administrative data. Med Care. 1998, 36: 8-27.CrossRefPubMed
47.
Liljas B: How to calculate indirect costs in economic evaluations. Pharmacoeconomics. 1998, 13 (1 Pt 1): 1-7.CrossRefPubMed
48.
Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L: The friction cost method for measuring indirect costs of disease. J Health Econ. 1995, 14: 171-189.CrossRefPubMed
49.
Institut für Arbeitsmarkt- und Berufsforschung (IAB): Projektion des Erwerbspersonenpotenzials bis 2050 – Annahmen und Datengrundlage. Ergebnisse aus der Projektarbeit des Instituts für Arbeitsmarkt- und Berufsforschung. 2005, Nürnberg: Institut für Arbeitsmarkt- und Berufsforschung (IAB), Forschungsbericht Nr. 25/2005]
50.
Statistisches Bundesamt: Bevölkerung und Erwerbstätigkeit – Sterbetafel Deutschland 2009/11. 2013, Wiesbaden: Statistisches Bundesamt
51.
Statistisches Bundesamt: Reallöhne, Nettoverdienste – Reallohnindex. 2013, Wiesbaden: Statistisches Bundesamt
52.
Smith DH, Gravelle H: The practice of discounting in economic evaluations of healthcare interventions. Int J Technol Assess Health Care. 2001, 17: 236-243.CrossRefPubMed
53.
Heckmann M, Kettner A, Rebien M: Offene Stellen im IV. Quartal 2008. Einbruch in der Industrie – Soziale Berufe Legen Zu. 2009, Nürnberg: [IAB-Kurzbericht: Aktuelle Analysen und Kommentare aus dem Institut für Arbeitsmarkt- und Berufsforschung]
54.
Gray JR, Bridges AB, Faed MJ, Pringle T, Baines P, Dean J, Boxer M: Ascertainment and severity of Marfan syndrome in a Scottish population. J Med Genet. 1994, 31: 51-54.CrossRefPubMedPubMedCentral
55.
Imbens GW: Nonparametric estimation of average treatment effects under exogeneity: a review. Rev Econ Stat. 2004, 86: 4-29.CrossRef
56.
Diamond A, Sekhon JS: Genetic matching for estimating causal effects: a general multivariate matching method for achieving balance in observational studies. Rev Econ Stat. 2012, 95: 932-945.CrossRef
57.
Abadie A, Imbens GW: Large Sample properties of matching estimators for average treatment effects. Econometrica. 2006, 74: 235-267.CrossRef
58.
Bertakis KD, Azari R: Patient gender differences in the prediction of medical expenditures. J Womens Health (Larchmt). 2010, 19: 1925-1932.CrossRef
59.
Kuo RN, Dong Y-H, Liu J-P, Chang C-H, Shau W-Y, Lai M-S: Predicting healthcare utilization using a pharmacy-based metric with the WHO’s Anatomic Therapeutic Chemical algorithm. Med Care. 2011, 49: 1031-1039.CrossRefPubMed
60.
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005, 43: 1130-1139.CrossRefPubMed
61.
Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika. 1983, 70: 41-55.CrossRef
62.
Austin PC: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009, 28: 3083-3107.CrossRefPubMedPubMedCentral
63.
64.
DiPrete TA, Gangl M: Assessing bias in the estimation of causal effects: Rosenbaum bounds on matching estimators and instrumental variables estimation with imperfect instruments. Sociol Methodol. 2004, 34: 271-310.CrossRef
65.
Rosenbaum PR: Sensitivity analysis in observational studies. Behavioral Science: Encyclopedia of Statistics in; 2005.CrossRef
66.
Bundesministerium für Gesundheit (BMG) – Federal Ministry of Health: Zahlen und Fakten zur Krankenversicherung. Bonn: Bundesministerium für Gesundheit (BMG) – Federal Ministry of Health; 2012. Mitgliederstatistik KM6 – Statistik über Versicherte Gegliedert Nach Status, Alter, Wohnort und Kassenart.
67.
Akobundu E, Ju J, Blatt L, Mullins CD: Cost-of-illness studies: a review of current methods. Pharmacoeconomics. 2006, 24: 869-890.CrossRefPubMed
68.
Rybczynski M, Mir TS, Sheikhzadeh S, Bernhardt AMJ, Schad C, Treede H, Veldhoen S, Groene EF, Kühne K, Koschyk D, Robinson PN, Berger J, Reichenspurner H, Meinertz T, von Kodolitsch Y: Frequency and age-related course of mitral valve dysfunction in the Marfan syndrome. Am J Cardiol. 2010, 106: 1048-1053.CrossRefPubMed
69.
van Karnebeek CDM, Naeff MSJ, Mulder BJM, Hennekam RCM, Offringa M: Natural history of cardiovascular manifestations in Marfan syndrome. Arch Dis Child. 2001, 84: 129-137.CrossRefPubMedPubMedCentral
70.
Sogawa M, Ohzeki H, Namura O, Hayashi J: Preoperative respiratory physiotherapy for a patient with severe respiratory dysfunction and annuloaortic ectasia. Ann Thorac Cardiovasc Surg. 2003, 9: 266-269.PubMed
71.
Stheneur C, Faivre L, Collod-Béroud G, Gautier E, Binquet C, Bonithon-Kopp C, Claustres M, Child AH, Arbustini E, Adès LC, Francke U, Mayer K, Arslan-Kirchner M, De Paepe A, Chevallier B, Bonnet D, Jondeau G, Boileau C: Prognosis factors in probands with an FBN1 mutation diagnosed before the age of 1 year. Pediatr Res. 2011, 69: 265-270.CrossRefPubMed
72.
Rybczynski M, Treede H, Sheikhzadeh S, Groene EF, Bernhardt AMJ, Hillebrand M, Mir TS, Kühne K, Koschyk D, Robinson PN, Berger J, Reichenspurner H, Meinertz T, von Kodolitsch Y: Predictors of outcome of mitral valve prolapse in patients with the Marfan syndrome. Am J Cardiol. 2011, 107: 268-274.CrossRefPubMed
73.
Blankart CR, Koch T, Linder R, Verheyen F, Schreyögg J, Stargardt T: Cost of illness and economic burden of chronic lymphocytic leukemia. Orphanet J Rare Dis. 2013, 8: 32.CrossRefPubMedPubMedCentral
74.
Kanavos P, van den Aardweg S, Schurer W: Diabetes Expenditure, Burden of Disease and Management in 5 EU Countries. London, UK: LSE Health, London School of Economics, 2012:1-105.
75.
Köster I, Huppertz E, Hauner H, Schubert I: Direct costs of diabetes mellitus in Germany – CoDiM 2000–2007. Exp Clin Endocrinol Diabetes. 2011, 119: 377-385.CrossRefPubMed
76.
Huber CA, Schneeweiss S, Signorell A, Reich O: Improved prediction of medical expenditures and health care utilization using an updated chronic disease score and claims data. J Clin Epidemiol. 2013, 66: 1118-1127.CrossRefPubMed
77.
Smeets HM, de Wit NJ, Hoes AW: Routine health insurance data for scientific research: potential and limitations of the Agis Health Database. J Clin Epidemiol. 2011, 64: 424-430.CrossRefPubMed
78.
Robinson PN: Classification and coding of rare diseases: overview of where we stand, rationale, why it matters and what it can change. Orphanet J Rare Dis. 2012, 7 (Suppl 2): A10.CrossRefPubMedCentral
79.
Orphanet: Orphanet: Prevalence of Rare Diseases: Bibliographic Data. France: Orphanet;2014:29-[Orphanet Report Series – Rare Diseases Collection]
80.
Braverman AC: Exercise and the Marfan syndrome. Med Sci Sports Exerc. 1998, 30 (10 Suppl): S387-S395.CrossRefPubMed
81.
Peters K, Apse K, Blackford A, McHugh B, Michalic D, Biesecker B: Living with Marfan syndrome: coping with stigma. Clin Genet. 2005, 68: 6-14.CrossRefPubMed
82.
Brouwer WBF, Meerding W-J, Lamers LM, Severens JL: The relationship between productivity and health-related QOL: an exploration. Pharmacoeconomics. 2005, 23: 209-218.CrossRefPubMed
83.
Lamers LM, Meerding W-J, Severens JL, Brouwer WBF: The relationship between productivity and health-related quality of life: an empirical exploration in persons with low back pain. Qual Life Res. 2005, 14: 805-813.CrossRefPubMed
84.
Rubin DB: Formal mode of statistical inference for causal effects. J Stat Planning Inference. 1990, 25: 279-292.CrossRef
85.
Taylor CM, Karet Frankl FE: Developing a strategy for the management of rare diseases. BMJ. 2012, 344: e2417.CrossRefPubMed
86.
Von Kodolitsch Y, Raghunath M, Nienaber CA: [Marfan syndrome: strategies of interdisciplinary care]. Dtsch Med Wochenschr. 1998, 123: 21-25.CrossRefPubMed
Metadata
Title
The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study
Authors
Dmitrij Achelrod
Carl Rudolf Blankart
Roland Linder
Yskert von Kodolitsch
Tom Stargardt
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2014
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-9-90

Other articles of this Issue 1/2014

Orphanet Journal of Rare Diseases 1/2014 Go to the issue

Research

Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset fabry mutation (IVS4 + 919G > A)

Research

Targeting under-diagnosis in hereditary hemorrhagic telangiectasia: a model approach for rare diseases?

Review

Simpson-Golabi-Behmel syndrome types I and II

Research

A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov

Research

Follow-up on pediatric patients with bronchiolitis obliterans treated with corticosteroid pulse therapy

Research

EXOSC3 mutations in pontocerebellar hypoplasia type 1: novel mutations and genotype-phenotype correlations